✓High-growth profile — revenue up +35.1% YoY with expanding US Equity exposure.
✓Healthy economics — 44% gross margin and 17% free-cash-flow margin.
✓New products and segments could unlock additional revenue streams.
⚠️ Key Risks
Execution delays, intensifying competition, and valuation compression if growth decelerates.
INDAPTUS THERAPEUTICS INC
INDP
Financial Trends
RevenueThe total money the company brought in from sales, before subtracting any costs.
$0▲ +0.0% YoY
Operating IncomeProfit from the core business after operating costs, but before interest and taxes. Negative means the core business isn’t profitable yet.
−$20M▲ +29.1% YoY
Free Cash FlowCash left over after running the business and paying for equipment/capex. Negative means the company is burning cash.
−$15M▲ +20.3% YoY
Shares OutstandingHow many shares exist. Rising means the company is issuing more shares, which dilutes (shrinks) each existing owner’s slice.
2.2M▲ +447.4% YoY
Net CashCash minus total debt. Positive = more cash than debt (financially strong); negative = more debt than cash (net debt).
$9M▲ +$3M YoY
StockOtter · stockotter.space
About INDAPTUS THERAPEUTICS INC
Indaptus Therapeutics, Inc. is a biotechnology company operating in the pre-clinical phase, dedicated to developing a range of immunotherapeutic products for the treatment of both cancer and viral infections. The firm's lead investigational compound, Decoy20, is currently progressing through Phase I clinical trials. This candidate is being evaluated for its capacity to elicit lasting therapeutic responses, either as a standalone agent or in combination with other treatments, for various conditions including lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as infections caused by the hepatitis B virus and human immunodeficiency virus. Initially incorporated in 2021 under the name Intec Parent, Inc., the company officially rebranded to Indaptus Therapeutics, Inc. in August of the same year. Its corporate headquarters are situated in New York, New York.
🦦
Otter Score Breakdown
How it's scoredFive components, each rated 1–5★ and equally weighted (20%), averaged to a 0–100 score:💎 Quality — gross margin🚀 Growth — revenue YoY⚖️ Valuation — P/S ratio⚡ Momentum — 30-day price change💧 Dilution — 1-yr share issuance (buybacks score higher)
StockOtter · stockotter.space